NDATOPICALCREAM
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANDEL is a topical hydrocortisone probutate cream indicated for inflammatory and pruritic dermatological conditions. It is a potent corticosteroid that works by reducing inflammation and suppressing immune response in skin tissue. This product targets patients requiring localized anti-inflammatory therapy for conditions such as eczema, dermatitis, and psoriasis.
$0.04MPart D
LOE ApproachingAs LOE approaches, PANDEL faces commercial contraction; expect smaller brand teams focused on generic transition planning and OTC positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PANDEL offers limited career growth opportunities given its LOE-approaching status and minimal brand team infrastructure (zero linked jobs). Roles available focus on lifecycle management, generic transition planning, and maintaining compliance rather than innovation or market expansion.
Brand ManagerField Sales Representative
Worked on PANDEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.